In Practice

Dr. Reshma Kewalramani named incoming president and CEO of Vertex Pharmaceuticals, former member ASN KHI Board of Directors

Announced July 25, Dr. Reshma Kewalramani will be promoted to president and CEO of Vertex Pharmaceuticals. She is currently the chief medical officer for the company and was previously a practicing nephrologist who earned her medical doctorate at Boston University and trained at Bigham & Women’s Hospital.

Dr. Kewalramani will be the first woman to run a large biotechnology firm. Vortex’s share price “rose 360% and its sales doubled to $3 billion annually” under the previous CEO, largely due the company’s pharmaceuticals used to treat cystic fibrosis.

KidneyX Patient Innovator Challenge: Kidney patients, care partners invited to submit ideas and innovations for national prize competition

The new prize competition seeks to identify ideas and solutions patients and care partners have developed to improve their daily life with kidney disease. The KidneyX Patient Innovator Challenge, funded by the National Kidney Foundation (NKF) invited individuals, communities, businesses, institutions, and not-for-profit organizations, among others, to submit ideas on how to improve therapeutic options and quality for life for people living with kidney disease.

ASN announces the first Editor-In-Chief of Kidney360, a new online open access journal

The American Society of Nephrology (ASN) today announced the appointment of Michael Allon, MD, as the first Editor-in-Chief of Kidney360, ASN’s new online journal launching in January 2020.

ASN and NIDDK initiatives to foster kidney research and investigators

Several initiatives have been implemented by NIDDK and ASN in order to foster kidney research and encourage research investigators as the NIH Division of Kidney, Urologic, & Hematologic Diseases (KUH) saw a 2% decrease in funding from the 2019 NIH budget.

This article includes a list of initiatives taken from an upcoming article in Kidney News March issue.

CNBC Report: New FDA-cleared, kidney disease early detection smartphone app

Outlined in a recent report from CNBC by Lori Ioannous (@Loriloannou1), chronic kidney disease is a “modern-day plague in the United States, driven in large part by the nation’s obesity epidemic”. 30 million Americans, or 1 in 9 adults, have chronic kidney disease, with diabetes and hypertension being major causes. “More than 510,000 kidney patients are now on dialysis, and over 100,000 are on the kidney transplant list”.

Study from UAB: acute kidney injury and kidney-resident macrophages

“Resident macrophages reprogram toward a developmental state after acute kidney injury” was published today, January 24th, in JCI Insight. The study with co-first authors and trainees in the NIH-funded UAB Medical Scientist Training Program, Jeremie M. Lever and Travis D. Hull, M.D., Ph.D., found that “during acute kidney injury (AKI) in a mouse model, kidney-resident macrophages are reprogrammed to a developmental state, resembling these same cells when they are found in newborn mice.

Kidney News Podcast on the Past and Future of the Kidney Health Initiative

ima_thumb.pngIn early December 2018, Prabir Roy-Chaudhury, MD, PhD, FASN, the outgoing American Society of Nephrology Co-Chair for KHI, and Raymond C. Harris, MD, FASN, who began his term as Co-Chair for KHI in 2019, recorded a discussion with ASN Executive Vice-President Tod Ibrahim.

Meet the ASN Foundation for Kidney Research Grant Recipients

The following articles are brief Q&A sessions with American Society of Nephrology (ASN) grant recipients. The sessions explore what research the individual is undertaking with the grant funds, their hopes for the research, career goals, and advice for others interested in applying for these grant funds.

Past Recipient Profiles

"Diagnostic Utility of Exome Sequencing for Kidney Disease" from The New England Journal of Medicine

“Exome sequencing in a cohort of over 3,000 patients demonstrated genetic causes of chronic kidney disease in about 10% of cases and genetic testing may aid in the treatment of these patients”.

Pages